Teva Pharmaceutical Industries Ltd ADR Stock
Teva Pharmaceutical Industries Ltd ADR shows a slight decrease today, losing -€0.100 (-0.370%) compared to yesterday.
Teva Pharmaceutical Industries Ltd ADR is currently one of the favorites of our community with 19 Buy predictions and no Sell predictions.
As a result the target price of 28 € shows a slightly positive potential of 4.87% compared to the current price of 26.7 € for Teva Pharmaceutical Industries Ltd ADR.
For the coming years our community has positive and negative things to say abot the Teva Pharmaceutical Industries Ltd ADR stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "Conscious of the environment" there were negative voices in the community.
Pros and Cons of Teva Pharmaceutical Industries Ltd ADR in the next few years
Pros
?
M***** P*******
?
B****
?
G***** c******* t* c**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Teva Pharmaceutical Industries Ltd ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Teva Pharmaceutical Industries Ltd ADR | -0.370% | 0.752% | 15.517% | 22.936% | 24.651% | 211.628% | 243.150% |
| Bayer AG ADR | 1.140% | 0.575% | 16.667% | 89.394% | 76.411% | -26.471% | -28.279% |
| Roche Holding AG ADR | -0.830% | 0.727% | 6.914% | 30.880% | 32.268% | 19.289% | 24.484% |
| Astrazeneca ADR | 0.640% | 1.282% | -1.250% | 23.438% | 23.438% | 24.214% | 92.683% |
Comments
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at Piper Sandler from $30.00 to $40.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $31.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat
Teva Pharmaceutical Industries (NYSE:TEVA) had its price target raised by analysts at JPMorgan Chase & Co. from $28.00 to $35.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for TEVA provided by MarketBeat